Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1 1

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 2Other hematologic neoplasm 2Gastrointestinal 2Thoracic 1Sarcoma 1Lymphoid 1Head & Neck 1CNS 1

Conditions

Neoplasms 2Colorectal Neoplasms 2Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Rectal Neoplasms 1Neuroblastoma 1Neoplasms by Site 1Neoplasms by Histologic Type 1Liver Neoplasms 1Laryngeal Diseases 1Hematologic Neoplasms 1Gliosarcoma 1Glioma 1Glioblastoma 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1

Interventions

Gemcitabine 69Fluorouracil 44pembrolizumab 43Oxaliplatin 42Capecitabine 40Bevacizumab 37Leucovorin 36Irinotecan 31Cisplatin 27Nivolumab 24Paclitaxel 21Cetuximab 21Panitumumab 20130-nm albumin-bound paclitaxel 20Sorafenib 18Albumin-Bound Paclitaxel 18Drug Therapy 15Docetaxel 15Cyclophosphamide 15Radiotherapy 14Blood Specimen Collection 14IFL protocol 12atezolizumab 11Exercise 11Taxes 10budigalimab 9Erlotinib Hydrochloride 9trametinib 8Folfox protocol 8Carboplatin 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms × capmatinib × Gastrointestinal × Clear all
NCT06988475 2025-11-24

DETERMINE

Cancer Research UK

Phase 2/3 Recruiting
30 enrolled
CNSGastrointestinalOther hematologic neoplasmSarcoma

Glioma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neuroblastoma, Sarcoma, Stomach Neoplasms, Hematologic Neoplasms

NCT02205398 2019-01-22

Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy

Novartis

Phase 1 Terminated
13 enrolled
GastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Laryngeal Diseases, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡